Cannell & Spears LLC Acquires 5,415 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cannell & Spears LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 50.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,055 shares of the biopharmaceutical company's stock after buying an additional 5,415 shares during the quarter. Cannell & Spears LLC's holdings in Regeneron Pharmaceuticals were worth $11,436,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after acquiring an additional 393,997 shares in the last quarter. Amundi raised its holdings in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $802,036,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock valued at $495,639,000 after purchasing an additional 22,538 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $18.18 during midday trading on Friday, reaching $592.46. The company's stock had a trading volume of 565,081 shares, compared to its average volume of 681,750. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $64.77 billion, a PE ratio of 15.45, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $589.64 and a 52 week high of $1,211.20. The business has a 50-day moving average price of $678.75 and a 200-day moving average price of $785.70.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.86 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REGN. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.